Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 25, 2026.

Mitochondrial response to nutrient availability and its role in metabolic disease

Arwen W Gao, Carles Cantó, Riekelt H Houtkooper

EMBO Molecular Medicine · 2014 · Review · CC BY

doi:10.1002/emmm.201303782

Abstract

Metabolic inflexibility is defined as an impaired capacity to switch between different energy substrates and is a hallmark of insulin resistance and type 2 diabetes mellitus (T2DM). Hence, understanding the mechanisms underlying proper metabolic flexibility is key to prevent the development of metabolic disease and physiological deterioration. An important downstream player in the effects of metabolic flexibility is the mitochondrion. The objective of this review was to describe how mitochondrial metabolism adapts to limited nutrient situations or caloric excess by changes in mitochondrial function or biogenesis, as well as to define the mechanisms propelling these changes. Altogether, this should pinpoint key regulatory points by which metabolic flexibility might be ameliorated in situations of metabolic disease.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 25, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Mitochondrial dysfunction is at the center of many metabolic disorders, such as obesity and type 2 diabetes mellitus (T2DM) (Andreux et al, ). It is widely believed that these disorders can be avoided by regular exercise and restricted food intake. However, compliance is poor and the metabolic syndrome epidemic is still spreading. Therefore, pharmacological approaches to target mitochondrial metabolism are being developed with the aim to treat these disorders.

The mitochondrion is an essential organelle in regulating a number of cellular processes, including energy (ATP) generation through nutrient breakdown, autophagy/mitophagy, and apoptosis. However, it is only sparsely described how these processes are influenced by situations of limited nutrient availability, such as fasting and caloric restriction (CR), or by excessive nutrient supply, such as high-fat feeding.

In this review, we aim to integrate the current knowledge on these areas and address three key questions: (i) What is the evidence for mitochondrial dysfunction in acquired metabolic disorders? (ii) How does energy stress impact on mitochondrial function, for instance at the level of biogenesis (AMPK/sirtuins) and mitochondrial dynamics (fusion/fission/mitophagy)? (iii) Is mitochondrial function a realistic target for pharmacological or nutritional intervention for the treatment of metabolic diseases?

Deficient metabolic flexibility as a cause for metabolic disease

The capacity of an organism, an organ, or a single cell to adapt fuel oxidation to fuel availability is termed metabolic flexibility (Galgani et al, ). This nomenclature was proposed as the capability to switch from fat metabolism in a fasting state to suppression of fat oxidation and enhanced glucose metabolism upon stimulation by insulin (Kelley & Mandarino, ). Active storage of nutrients and efficient disposal of blood glucose after a meal are characteristic of healthy metabolism (Storlien et al, ). In turn, metabolically inflexible individuals fail to adapt their fuel preference to changes in carbohydrate or lipid supplies (Galgani et al, ).

Imbalanced energy homeostasis is a characteristic of obese and type 2 diabetes mellitus (T2DM) patients. Interestingly, metabolic inflexibility can already be observed in pre-diabetic individuals suffering from insulin resistance (Corpeleijn et al, ), limiting the ability to switch from fatty acid breakdown to fat storage after a meal and vice versa (Kelley, ). Diverse mitochondrial parameters vary between insulin-resistant and insulin-sensitive subjects, such as mitochondrial number, structure, and function. This suggests that mitochondrial dysfunction might contribute to metabolic inflexibility and insulin resistance (Galgani et al, ).

Mitochondrial deficiencies limit the capacity of oxidative tissues to adapt fat oxidation to fat availability, leading to the accumulation of lipids in non-adipose tissues, such as skeletal muscle. Intramyocellular lipids (IMCL) are used as fuel during regular exercise (Coen & Goodpaster, ), but lipid accumulation in non-adipose tissues is also highly associated with insulin resistance (Canto & Auwerx,; Corpeleijn et al,; Schooneman et al, ). For instance, IMCL levels were increased in first-level relatives of T2DM patients and associated with impaired insulin-stimulated glucose uptake in muscle (Pan et al, ). The link between IMCL and insulin resistance was confirmed in biopsies from individuals with obesity and T2DM (Goodpaster et al,; Coen & Goodpaster, ). In obese individuals, impaired mitochondrial function might contribute to lower IMCL turnover and lead to lipotoxicity (Schooneman et al, ). These lipids interfere with insulin signaling and represent one of the key aspects that could contribute to insulin resistance in situations of high-fat feeding or lipid infusion (Pan et al,; Krssak et al,; Goodpaster et al, ).

Gene-clustering approaches supported the above hypothesis by demonstrating that muscles from T2DM patients display downregulation of lipid oxidation and mitochondrial metabolism genes (Mootha et al,; Patti et al, ). Mitochondrial deficiencies were also characteristic in age-related insulin resistance (Petersen et al, ). In a parallel study, insulin resistance in the skeletal muscle of insulin-resistant offspring of T2DM patients was associated with dysregulation of intramyocellular fatty acid metabolism, possibly due to deficiencies in mitochondrial oxidative phosphorylation capacity (Petersen et al, ). In light of the above data, increasing mitochondrial content could constitute a promising preventive and therapeutic approach against insulin resistance and T2DM (Canto & Auwerx, ). Several pharmacological and nutritional interventions have been designed in this direction, which protect against the development of insulin resistance and high-fat diet (HFD)-induced metabolic damage (e.g., resveratrol or PPARβ agonists) (Andreux et al, ).

Although the correlative evidence around mitochondrial dysfunction and the development of metabolic diseases is overwhelming, some evidence casts a shadow of doubt on its causal role. For instance, some of the mouse models that overexpress proteins promoting mitochondrial biogenesis display a largely enhanced mitochondrial content in skeletal muscle, but are insulin resistant (Finck et al,; Choi et al, ). Along the same line, insulin-stimulated glucose sensitivity is increased in some mouse models of mitochondrial dysfunction (Wredenberg et al,; Pospisilik et al,; Zechner et al, ). Also, mitochondrial dysfunction is observed only after prolonged high-fat feeding, while insulin resistance develops earlier (Hancock et al, ). Finally, T2DM patients, despite having a 30% lower mitochondrial content, have higher mitochondrial oxidation rates and do not have an intrinsic problem to increase their whole-body fat oxidation rate during exercise (Larsen et al,; Holloszy, ). Similarly, the decreased mitochondrial content in insulin-resistant old individuals seems to be rather linked to decreased physical activity and can be perfectly enhanced in response to exercise (Broskey et al, ). This highlights how some tissues, such as human muscle, might actually have a notable reserve of respiratory capacity, and that minor changes in their mitochondrial content might not be enough to limit resting respiratory needs. Indeed, the concept of reserve respiratory capacity in humans is not new. It was initially characterized in diverse human cell lines, where COX activity was found to be higher than that required to support endogenous respiration rates, allowing this way some adaptability to higher respiratory needs (Villani et al, ). Therefore, while many strategies to increase mitochondrial function rendered protection against insulin resistance and T2DM, further studies are required to clarify the link between mitochondrial deficiency and insulin resistance. Furthermore, future studies will have to address mitochondrial functional quality rather than quantity, as will become apparent in the following sections.

Mechanisms controlling mitochondrial metabolism

In order to maintain metabolic homeostasis, organisms adjust the capacity and efficiency of ATP generation to changes in energetic demand and supply. Mitochondrial activity can be controlled through at least two major mechanisms: acute ones, aimed to qualitatively modify mitochondrial function, and longer-term transcriptional mechanisms, aimed to increase mitochondrial number.

Acute mechanisms for the control of mitochondrial metabolism

Acute mechanisms to modify mitochondrial function affect the intrinsic ability of mitochondria to generate ATP per molecule of nutrient or per unit of time. Two major mechanisms have potently emerged, namely changes in mitochondrial architecture or dynamics, and regulation through post-translational mechanisms.

Mitochondrial dynamics

Changes in mitochondrial architecture are dynamic and involve a delicate balance between proteins promoting fusion [e.g., mitofusin (Mfn) 1 and Mfn2, and optic atrophy 1 (Opa1)] and fission [e.g., fission 1 (Fis1), mitochondrial fission factor (Mff), and dynamin-related protein 1 (Drp1)] (Youle & van der Bliek, ). Cells under a well-fed condition maintain their mitochondria in a separated (or fragmented) state, while under fasting or starved conditions, mitochondria tend to persist in a connected (or fused) state (Gomes et al, ). This suggests that adaption of bioenergetics involves remodeling of mitochondrial architecture. Indeed, as described below, changes in mitochondrial architecture can affect respiratory complex assembly and the proper coupling of respiration to ATP synthesis (Gomes et al, ). In addition, the transitions between fragmented and fused states allow mitochondria to reorganize and dispose damaged elements through mitophagy (Fig 1). Notably, the mitochondrial life cycle is attenuated when the fusion or fission pathways are not functioning properly, leading to mitochondrial dysfunction. Dysfunctional mitochondria, especially those with dissipated membrane potential, are recognized by the mitophagic machinery and broken down rapidly (Youle & Narendra, ). Thus, mitochondrial architectural changes might offer a new molecular mechanism to connect nutrient availability to bioenergetic adaptations (Liesa & Shirihai, ).

Post-translational modifications

Among different post-translational modifications, protein acetylation has recently emerged as another reversible mechanisms linking the metabolic state and mitochondrial function (Figs 2A and 3A). Mitochondria contain many acetylated proteins, often at several residues. Reversibly acetylated mitochondrial proteins can be found in most mitochondrial functions, including oxidative phosphorylation (Ahn et al, ), reactive oxygen species metabolism (Qiu et al,; Chen et al, ) and fatty acid metabolism (Hirschey et al, ). Upon fasting and high-fat feeding, the acetylation pattern of mitochondrial proteins strongly changes. This is due to changes in the balances between acetylation and deacetylation rates, for instance involving the mitochondrial NAD+-dependent deacetylase SIRT3 (Houtkooper et al, ). This opens the possibility that coordinated changes in mitochondrial acetylation serve to regulate mitochondrial acetyl-CoA levels and trigger appropriate responses. Therefore, understanding the specificity of mitochondrial acetylation dynamics will be a key to evaluate the impact of nutritional states on mitochondrial function. In addition to acetylation, novel mitochondrial post-translational modifications have emerged that may reflect the metabolic state, including succinylation and malonylation (Du et al,; Peng et al, ). Although the physiological role of these modifications is not yet understood, its reliance on the NAD+-dependent SIRT5 suggests a metabolic function analogous to SIRT3-dependent acetylation.

Transcriptional regulation of mitochondrial metabolism

Cellular oxidative capacity can also be controlled through increasing its mitochondrial content. Mitochondrial biogenesis is achieved through orchestrated induction of several transcriptional regulators, whose activity is critically determined by energetic demands (Andreux et al, ) (Figs 2B, 3B and C). A key family of transcription factors that connects lipid metabolism with transcriptional outputs is the PPARs. PPARs are nuclear receptors that directly bind specific lipid species that generally increase upon cellular fat overflow in the cells. There are three PPARs: α, β (also known as δ) and γ. Each of these binds specific lipid species as ligands and controls different transcriptional programs linked to lipid metabolism (Wahli & Michalik, ). For example, PPARα activates fatty acid oxidation by inducing lipid oxidation genes in mitochondria and peroxisomes (Yoon, ). PPARβ/δ triggers fatty acid β-oxidation in muscle and adipose tissue, which results in enhanced fat breakdown (Wang et al,; Varga et al, ). In contrast, PPARγ controls lipogenic and adipocyte differentiation gene expression and activates lipid storage (Varga et al,; Wahli & Michalik, ).

The PPARγ coactivator 1α, PGC-1α, regulates mitochondrial biogenesis by coactivating various transcription factors and nuclear receptors. The activity of PGC-1α is regulated by post-translational modifications that fine-tune mitochondrial metabolism with environmental challenges (Canto & Auwerx, ). For example, PGC-1α activity is determined by its acetylation status. In the basal state, PGC-1α is acetylated, which dampens PGC-1α activity. Upon nutrient stress, the NAD+-dependent deacetylase SIRT1 activates PGC-1α, a reaction that is rate-limited by availability of the metabolite NAD+ (Houtkooper et al, ). Hence, increasing NAD+ content leads to higher SIRT1 activity (Canto & Auwerx, ). NAD+ is a highly dynamic molecule whose cellular abundance depends on the metabolic state. Therefore, SIRT1 is optimally positioned to translate the metabolic state to transcriptional outputs on mitochondrial biogenesis through the deacetylation of PGC-1α. Indeed, different situations of energy restriction, including fasting and exercise, increase NAD+ levels and trigger SIRT1/PGC-1α-dependent mitochondrial adaptation (Lin et al,; Houtkooper et al, ). In addition to PGC-1α, SIRT1 also deacetylates forkhead box O (FOXO) transcription factors, enhancing the expression of lipid oxidation and oxidative stress protection genes (Brunet et al, ). Interestingly, FOXOs can also act as critical regulators of mitochondrial homeostasis through, at least, two additional means: (i) by regulating the expression of Mul1, a mitochondrial E3 ubiquitin ligase that controls Mfn2 degradation rates (Lokireddy et al, ), and (ii) by regulating the expression of the PTEN-induced kinase 1 (PINK1), a key component of the mitophagy machinery (Mei et al, ). This intricate transcriptional network constitutes an excellent mechanism to fine-tune oxidative metabolism and longer-term adaptations.

Acute regulation

Nutrient scarcity in organisms is linked to an increase in circulating glucagon and other stress hormones, such as norepinephrine, which generally increase intracellular cAMP levels and PKA signaling (Fig 2A). Under these circumstances, mitochondrial fusion is typically observed (Liesa & Shirihai, ) (Fig 2A). Elongated mitochondria upon fasting possess more cristae and increased levels of dimerization and activity of ATP synthase, ensuring a better coupling of fuel oxidation with ATP synthesis (Gomes et al, ). These changes in mitochondrial cristae content could also contribute to an optimal assembly of so-called respiratory supercomplexes, promoting a more efficient electron flux through the respiratory chain (Cogliati et al, ). On the other hand, mitochondria that fail to elongate are degraded by mitophagy. But, how does this happen at the molecular level? Mitochondrial fusion upon energy stress requires the mitochondrial oligomerization of Drp1, which actively shuttles between mitochondria and the cytosol. The activation of cAMP/PKA upon nutrient starvation leads to phosphorylation of Drp1, preventing its stable docking on the mitochondrial surface and therefore mitochondrial fission (Cereghetti et al, ) (Fig 2A). While this is the most solidly described mechanism for the acute regulation of mitochondrial architecture upon energy deprivation, there might be additional layers of regulation, as reviewed recently (Escobar-Henriques & Anton,; Otera et al, ), even though their participation on metabolic adaptations has been poorly explored.

The SIRT3 deacetylase enzyme has also emerged as a key regulator of mitochondrial activity (Lombard et al, ). Upon fasting, SIRT3 expression is rapidly induced and deacetylates key residues on mitochondrial proteins (Hirschey et al, ). The increased SIRT3 activity facilitates optimal fatty acid oxidation, mitochondrial electron transfer and protection against reactive oxygen special all at once (He et al, ). Interestingly, SIRT3 also deacetylates and elevates the GTPase activity of the inner membrane fusion protein OPA1, thereby favoring mitochondrial elongation (Samant et al, ). It is not clear yet whether the increase in SIRT3 activity upon nutrient deprivation is regulated exclusively at the transcriptional level. Being NAD+ dependent, it seems likely that SIRT3 is controlled by mitochondrial NAD+ levels. Indeed, exogenously providing NAD+ precursors can enhance SIRT3 activity in mammalian cells and tissues (Canto et al, ) and rescue deficient SIRT3 activity in a model for complex I deficiency (Karamanlidis et al, ). This indicates that fluctuations in NAD+ levels during nutrient restriction might contribute in the control of SIRT3 activity. Intriguingly, CR enhances mitochondrial protein acetylation in diverse tissues, such as liver, heart, and kidney (Schwer et al, ). This may be the result of fat overflow into these tissues. Indeed, the global increase in protein acetylation does not reflect how specific residues are deacetylated upon CR (Hebert et al, ). This suggests that SIRT3 regulates more accessible hydrophilic residues, while residues on hydrophobic regions are less accessible and prone to become acetylated.

Transcriptional responses

Prolonged nutrient stress requires adaptation through transcriptional responses. A primordial sensor for energy stress is the AMP-activated protein kinase (AMPK), an enzyme that is activated by increases in the AMP/ATP ratio (Fig 2B). Upon activation, AMPK activates catabolic pathways and switches off energy-consuming processes. One of these targets is PGC-1α (Jager et al, ). Upon phosphorylation, PGC-1α is recognized as a deacetylation target by SIRT1 (Canto & Auwerx,; Iwabu et al, ). As a consequence, PGC-1α coactivates a set of transcription factors involved in mitochondrial metabolism, including estrogen-related receptors, nuclear respiratory factors, and PPARs (Andreux et al, ). This two-step activation of PGC-1α might be a conserved mechanism for AMPK to confer specificity among the various targets of SIRT1 (Canto & Auwerx, ). Other effectors of AMPK are the FOXO transcription factors (Greer et al, ), which are also a target for deacetylation by SIRT1 (Brunet et al, ). The deacetylated FOXO will then contribute to the regulation of mitochondrial function and lipid metabolism (Canto & Auwerx, ). A second connection between fasting-induced transcriptional adaptation and mitochondrial dynamics lies in the transcriptional regulation exerted by fasting-related hormones. So far, however, this has been a largely unexplored territory. For example, dexamethasone induces Drp1 expression in liver cells and thereby changes mitochondrial morphology and metabolism that favor gluconeogenic procedures (Hernandez-Alvarez et al, ). To what extent these pathways are also active in other tissues and in other physiological conditions needs to be determined.

Additional interest on how nutrient scarcity modulates mitochondrial function comes from the fact that CR is the most consistent physiological intervention to improve health and extend lifespan across a wide range of organisms (Fontana et al,; Houtkooper et al, ). The relationship between CR and mitochondrial regulation is, however, still under debate. Initial evidence indicated that CR enhances mitochondrial content (Nisoli et al, ). These findings were rapidly accepted and have led to the concept that CR induces mitochondrial biogenesis, even though some studies found no increase in mitochondrial protein content upon CR (Hancock et al, ). Interestingly, a recent report indicates that CR enhances mitochondrial function without changes in mitochondrial content or biogenesis (Lanza et al, ). The mechanisms underlying this enhanced function are, however, not clear. A conciliatory hypothesis would be that CR protects against mitochondrial dysfunction by improving mitochondrial dynamics and the efficiency of mitophagic processes.

Acute regulation

Lipid overloading promotes fast and transient changes in mitochondrial architecture. Studies in Zucker rats and obese humans have shown that Mfn2 was strongly decreased in their skeletal muscle tissues compared to the control groups, which was associated with smaller mitochondrial network and size (Bach et al, ). Along with this fusion deficiency, mitochondrial fission is induced within minutes after a lipid overload in INS-1 cells (Molina et al,; Liesa & Shirihai, ) (Fig 3A). Additional recent efforts have elegantly demonstrated that lipid overload also enhances norepinephrine-induced mitochondrial fission in brown adipocytes in vivo and ex vivo (Wikstrom et al, ). These mitochondrial fission events promoted mitochondrial uncoupled respiration (Liesa & Shirihai,; Wikstrom et al, ). A key issue that requires further study is the basic mechanism by which fission enhances mitochondrial uncoupling. In this sense, evaluating whether fission alters cristae structure and supercomplex assembly will be interesting in the future. Irrespective of the mechanism, mitochondrial uncoupling upon lipid loading may be a way to dissipate energy and prevent detrimental lipid deposition in the cell (Liesa & Shirihai, ). In line with the above observations, obese patients display a largely fragmented mitochondrial network in skeletal muscle (Bach et al, ). The analysis of mice with mitochondrial fusion or fission defects will be key to evaluate the relevance of fusion/fission in the acute adaptation to nutrient challenges. Considering that global deletion of key mitochondrial dynamics proteins, such as Mfn1, Mfn2, Opa1 or Drp1, leads to embryonic lethality (Chen et al,; Davies et al,; Ishihara et al, ), tissue-specific knockout models are currently being explored. Indeed, deletion of Mfn2 in the liver disrupts mitochondria-ER connectivity and thereby induces ER stress-mediated susceptibility to metabolic disease upon high-fat feeding (Sebastian et al, ), indicating once more that the regulation of mitochondrial dynamics is essential to meet metabolic challenges. Defective mitochondrial dynamics and mitochondrial-ER communication in hypothalamic POMC and AgRP neurons might actually modify feeding behavior and whole-body energy homeostasis (Dietrich et al,; Schneeberger et al, ).

Dietary excess of lipids also dramatically changes mitochondrial protein acetylation. One week of HFD enhanced SIRT3 levels and prevented mitochondrial hyperacetylation despite the higher levels of lipid substrates (Hirschey et al, ). This increase in SIRT3 may represent a cellular adaptation to cope with the need to use fatty acid oxidation as the main path for energy production. Conversely, prolonged HFD dramatically decreases SIRT3 expression, correlating with the appearance of mitochondrial hyperacetylation and mitochondrial dysfunction (Hirschey et al, ). To date, it is still unclear why the initial adaptations tend to disappear with time, ultimately driving the organism into metabolic disease.

Transcriptional responses

Changes in mitochondrial dynamics are apparent in the acute phase of caloric excess. Still, however, Mfn2 expression is also reduced, possibly through transcriptional regulation. Similar to many mitochondrial genes, Mfn2 expression is controlled by PGC-1α (Soriano et al, ), suggesting that decreased PGC-1α activity explains the defects in Mfn2 observed in obese and T2DM individuals. Indeed, HFD in mice leads to hyperacetylated, inactive, PGC-1α (Coste et al, ). This is likely regulated at several levels. During HFD, SIRT1 expression is reduced, while the GCN5 acetyltransferase, which acetylates PGC-1α, is expressed at higher levels (Coste et al, ). HFD also reduces the NAD+ content in diverse tissues, which is likely to impair SIRT1 activation (Kim et al,; Yoshino et al, ) (Fig 3B). The resulting hyperacetylation of PGC-1α renders it unable to properly coactivate target transcription factors, leading to decreased mitochondrial biogenesis.

The expression of repressive transcriptional regulators, such as the nuclear receptor corepressor 1 (NCoR1), is also enhanced by HFD, repressing genes that control mitochondrial activity and contributing to the excessive calorie storage (Yamamoto et al, ) (Fig 3C). In fact, PGC-1α and NCoR1 oppositely regulate several transcription factors, including nuclear respiratory factors, estrogen-related receptors and PPARs (Scarpulla,; Andreux et al,; Mottis et al, ). An interesting question is why mitochondria can perfectly respond to acute caloric excess, but fail to do so when the intervention persists for a long time. In the initial phases of HFD (up to 1 month), mitochondrial and lipid oxidation genes are upregulated to meet the higher flux of lipid substrates (Garcia-Roves et al,; Hancock et al, ). However, prolonged lipid overload compromises mitochondrial function. The threshold for this to happen and the reason behind it still need to be solved, but it seems likely that this defective long-term protection contributes to lipid accumulation and insulin resistance.

Discussion

Revealing the causal link between mitochondrial function and metabolic disorders continues to be a great challenge. Based on the evidence during the last decade, the concept that T2DM and obesity are linked to mitochondrial dysfunction has gathered momentum in the scientific community. However, most of the data supporting this concept are based on the fact that reductions in the content of mitochondrial enzymes and alterations in mitochondrial shape were observed in the muscles from patients with T2DM. This went hand in hand with the accumulation of lipids that could impair insulin signaling. It was therefore hypothesized that increasing mitochondrial function might be a valuable strategy to boost lipid oxidation, prevent lipid accumulation, and thereby treat insulin resistance. However, the above-mentioned hypothesis has three conflicting points: (i) mitochondrial biogenesis can occur simultaneously to insulin resistance, (ii) disruption of mitochondrial function leads to increases in basal and insulin-stimulated glucose uptake in some models, and (iii) most studies actually show that fat oxidation is increased in obese, insulin-resistant individuals and T2DM patients.

While most studies observe mitochondria in a steady state, mitochondrial function can dramatically change through fusion/fission or post-translational modifications of mitochondrial proteins. We propose that metabolic flexibility and mitochondrial fitness might not necessarily correlate with mitochondrial number or mitochondrial protein content, but to the ability to adapt mitochondrial activity and biogenesis to external stimuli. Indeed, higher mitochondrial content could also be due to deficiencies in mitochondrial recycling mechanisms and in fact be linked to mitochondrial dysfunction. This is the case, for example, in muscle-specific AMPK knockouts, which display enlarged but dysfunctional mitochondria (O'Neill et al, ).

In light of the evidence reviewed here, the evaluation of mitochondrial content as a readout for function might lead to conflictive observations on the relationship between diverse pathologies, lipid oxidation rates, and true mitochondrial function. This advocates for the need to determine various additional aspects of mitochondrial well-being to certify changes in mitochondrial function within pathophysiological states. Still, some key questions remain unanswered, such as (i) why does mitochondrial content decline upon a certain length of fat overfeeding and how can this be prevented, and (ii) can strategies aimed to enhance insulin sensitivity be successful without proper mitochondrial fitness? Needless to say, interesting times lie ahead.

Pending issues%

How does mitochondrial dynamics influence metabolic activity and quality control in response to physiological cues?

Solidify the contribution of mitochondrial dynamics in the development of human metabolic and cardiovascular complications.

Identify pharmaceutical compounds that improve mitochondrial metabolism in humans.

Determine metabolomic and lipidomic footprints of metabolic flexibility.

References 85

  1. 1.

    Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, Deng CX, Finkel T. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA. 2008;105:14447-14452.

    Not in our library10.1073/pnas.0803790105

  2. 2.

    Andreux PA, Houtkooper RH, Auwerx J. Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov. 2013;12:465-483.

    Not in our library10.1038/nrd4023

  3. 3.

    Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, Daugaard JR, Lloberas J, Camps M, Zierath JR, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem. 2003;278:17190-17197.

    Not in our library10.1074/jbc.m212754200

  4. 4.

    Broskey NT, Greggio C, Boss A, Boutant M, Dwyer A, Schlueter L, Hans D, Gremion G, Kreis R, Boesch C, et al. Skeletal muscle mitochondria in the elderly: effects of physical fitness and exercise training. J Clin Endocrinol Metab. 2014.

    Not in our library10.1210/jc.2013-3983

  5. 5.

    Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303:2011-2015.

    Not in our library10.1126/science.1094637

  6. 6.

    Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol. 2009;20:98-105.

    Not in our library10.1097/mol.0b013e328328d0a4

  7. 7.

    Canto C, Auwerx J. AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci. 2010;67:3407-3423.

    Not in our library10.1007/s00018-010-0454-z

  8. 8.

    Canto C, Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev. 2012;64:166-187.

    Not in our library10.1124/pr.110.003905

  9. 9.

    Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012;15:838-847.

    Not in our library10.1016/j.cmet.2012.04.022

  10. 10.

    Cereghetti GM, Stangherlin A, Martins de Brito O, Chang CR, Blackstone C, Bernardi P, Scorrano L. Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. Proc Natl Acad Sci USA. 2008;105:15803-15808.

    Not in our library10.1073/pnas.0808249105

  11. 11.

    Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003;160:189-200.

    Not in our library10.1083/jcb.200211046

  12. 12.

    Chen Y, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S, Xiong Y. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep. 2011;12:534-541.

    Not in our library10.1038/embor.2011.65

  13. 13.

    Choi CS, Befroy DE, Codella R, Kim S, Reznick RM, Hwang YJ, Liu ZX, Lee HY, Distefano A, Samuel VT, et al. Paradoxical effects of increased expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. Proc Natl Acad Sci USA. 2008;105:19926-19931.

    Not in our library10.1073/pnas.0810339105

  14. 14.

    Coen PM, Goodpaster BH. Role of intramyocellular lipids in human health. Trends Endocrinol Metab. 2012;23:391-398.

    Not in our library10.1016/j.tem.2012.05.009

  15. 15.

    Cogliati S, Frezza C, Soriano ME, Varanita T, Quintana-Cabrera R, Corrado M, Cipolat S, Costa V, Casarin A, Gomes LC, et al. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell. 2013;155:160-171.

    Not in our library10.1016/j.cell.2013.08.032

  16. 16.

    Corpeleijn E, Saris WH, Blaak EE. Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obes Rev. 2009;10:178-193.

    Not in our library10.1111/j.1467-789x.2008.00544.x

  17. 17.

    Coste A, Louet JF, Lagouge M, Lerin C, Antal MC, Meziane H, Schoonjans K, Puigserver P, O'Malley BW, Auwerx J. The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{alpha}. Proc Natl Acad Sci USA. 2008;105:17187-17192.

    Not in our library10.1073/pnas.0808207105

  18. 18.

    Davies VJ, Hollins AJ, Piechota MJ, Yip W, Davies JR, White KE, Nicols PP, Boulton ME, Votruba M. Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum Mol Genet. 2007;16:1307-1318.

    Not in our library10.1093/hmg/ddm079

  19. 19.

    Dietrich MO, Liu ZW, Horvath TL. Mitochondrial dynamics controlled by mitofusins regulate Agrp neuronal activity and diet-induced obesity. Cell. 2013;155:188-199.

    Not in our library10.1016/j.cell.2013.09.004

  20. 20.

    Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, Kim J, Woo J, Kim JH, Choi BH, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science. 2011;334:806-809.

    Not in our library10.1126/science.1207861

  21. 21.

    Escobar-Henriques M, Anton F. Mechanistic perspective of mitochondrial fusion: tubulation vs. fragmentation. Biochim Biophys Acta. 2013;1833:162-175.

    Not in our library10.1016/j.bbamcr.2012.07.016

  22. 22.

    Finck BN, Bernal-Mizrachi C, Han DH, Coleman T, Sambandam N, LaRiviere LL, Holloszy JO, Semenkovich CF, Kelly DP. A potential link between muscle peroxisome proliferator-activated receptor-alpha signaling and obesity-related diabetes. Cell Metab. 2005;1:133-144.

    Not in our library10.1016/j.cmet.2005.01.006

  23. 23.

    Fontana L, Partridge L, Longo VD. Extending healthy life span–from yeast to humans. Science. 2010;328:321-326.

    Not in our library10.1126/science.1172539

  24. 24.

    Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin resistance. Am J Physiol Endocrinol Metab. 2008;295:E1009-E1017.

    Not in our library10.1152/ajpendo.90558.2008

  25. 25.

    Garcia-Roves P, Huss JM, Han DH, Hancock CR, Iglesias-Gutierrez E, Chen M, Holloszy JO. Raising plasma fatty acid concentration induces increased biogenesis of mitochondria in skeletal muscle. Proc Natl Acad Sci USA. 2007;104:10709-10713.

    Not in our library10.1073/pnas.0704024104

  26. 26.

    Gomes LC, Di Benedetto G, Scorrano L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat Cell Biol. 2011;13:589-598.

    Not in our library10.1038/ncb2220

  27. 27.

    Goodpaster BH, Theriault R, Watkins SC, Kelley DE. Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism. 2000;49:467-472.

    Not in our library10.1016/s0026-0495(00)80010-4

  28. 28.

    Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP, Brunet A. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem. 2007;282:30107-30119.

    Not in our library10.1074/jbc.m705325200

  29. 29.

    Hancock CR, Han DH, Chen M, Terada S, Yasuda T, Wright DC, Holloszy JO. High-fat diets cause insulin resistance despite an increase in muscle mitochondria. Proc Natl Acad Sci USA. 2008;105:7815-7820.

    Not in our library10.1073/pnas.0802057105

  30. 30.

    He W, Newman JC, Wang MZ, Ho L, Verdin E. Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol Metab. 2012;23:467-476.

    Not in our library10.1016/j.tem.2012.07.004

  31. 31.

    Hebert AS, Dittenhafer-Reed KE, Yu W, Bailey DJ, Selen ES, Boersma MD, Carson JJ, Tonelli M, Balloon AJ, Higbee AJ, et al. Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol Cell. 2013;49:186-199.

    Not in our library10.1016/j.molcel.2012.10.024

  32. 32.

    Hernandez-Alvarez MI, Paz JC, Sebastian D, Munoz JP, Liesa M, Segales J, Palacin M, Zorzano A. Glucocorticoid modulation of mitochondrial function in hepatoma cells requires the mitochondrial fission protein Drp1. Antioxid Redox Signal. 2013;19:366-378.

    Not in our library10.1089/ars.2011.4269

  33. 33.

    Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464:121-125.

    Not in our library10.1038/nature08778

  34. 34.

    Holloszy JO. “Deficiency” of mitochondria in muscle does not cause insulin resistance. Diabetes. 2013;62:1036-1040.

    Not in our library10.2337/db12-1107

  35. 35.

    Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010a;31:194-223.

    Not in our library10.1210/er.2009-0026

  36. 36.

    Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 2012;13:225-238.

    Not in our library10.1038/nrm3293

  37. 37.

    Houtkooper RH, Williams RW, Auwerx J. Metabolic networks of longevity. Cell. 2010b;142:9-14.

    Not in our library10.1016/j.cell.2010.06.029

  38. 38.

    Ishihara N, Nomura M, Jofuku A, Kato H, Suzuki SO, Masuda K, Otera H, Nakanishi Y, Nonaka I, Goto Y, et al. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat Cell Biol. 2009;11:958-966.

    Not in our library10.1038/ncb1907

  39. 39.

    Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, Yamaguchi M, Namiki S, Nakayama R, Tabata M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010;464:1313-1319.

    Not in our library10.1038/nature08991

  40. 40.

    Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA. 2007;104:12017-12022.

    Not in our library10.1073/pnas.0705070104

  41. 41.

    Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC, Suthammarak W, Gong G, Sedensky MM, Morgan PG, Wang W, Tian R. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab. 2013;18:239-250.

    Not in our library10.1016/j.cmet.2013.07.002

  42. 42.

    Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest. 2005;115:1699-1702.

    Not in our library10.1172/jci25758

  43. 43.

    Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes. 2000;49:677-683.

    Not in our library10.2337/diabetes.49.5.677

  44. 44.

    Kim HJ, Kim JH, Noh S, Hur HJ, Sung MJ, Hwang JT, Park JH, Yang HJ, Kim MS, Kwon DY, et al. Metabolomic analysis of livers and serum from high-fat diet induced obese mice. J Proteome Res. 2011;10:722-731.

    Not in our library10.1021/pr100892r

  45. 45.

    Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 1999;42:113-116.

    Not in our library10.1007/s001250051123

  46. 46.

    Lanza IR, Zabielski P, Klaus KA, Morse DM, Heppelmann CJ, Bergen HR, Dasari S, Walrand S, Short KR, Johnson ML, et al. Chronic caloric restriction preserves mitochondrial function in senescence without increasing mitochondrial biogenesis. Cell Metab. 2012;16:777-788.

    Not in our library10.1016/j.cmet.2012.11.003

  47. 47.

    Larsen S, Ara I, Rabol R, Andersen JL, Boushel R, Dela F, Helge JW. Are substrate use during exercise and mitochondrial respiratory capacity decreased in arm and leg muscle in type 2 diabetes? Diabetologia. 2009;52:1400-1408.

    Not in our library10.1007/s00125-009-1353-4

  48. 48.

    Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013;17:491-506.

    Not in our library10.1016/j.cmet.2013.03.002

  49. 49.

    Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science. 2000;289:2126-2128.

    Not in our library10.1126/science.289.5487.2126

  50. 50.

    Lokireddy S, Wijesoma IW, Teng S, Bonala S, Gluckman PD, McFarlane C, Sharma M, Kambadur R. The ubiquitin ligase Mul1 induces mitophagy in skeletal muscle in response to muscle-wasting stimuli. Cell Metab. 2012;16:613-624.

    Not in our library10.1016/j.cmet.2012.10.005

  51. 51.

    Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, Kim J, Yancopoulos G, Valenzuela D, Murphy A, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. 2007;27:8807-8814.

    Not in our library10.1128/mcb.01636-07

  52. 52.

    Mei Y, Zhang Y, Yamamoto K, Xie W, Mak TW, You H. FOXO3a-dependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation. Proc Natl Acad Sci USA. 2009;106:5153-5158.

    Not in our library10.1073/pnas.0901104106

  53. 53.

    Molina AJ, Wikstrom JD, Stiles L, Las G, Mohamed H, Elorza A, Walzer G, Twig G, Katz S, Corkey BE, et al. Mitochondrial networking protects beta-cells from nutrient-induced apoptosis. Diabetes. 2009;58:2303-2315.

    Not in our library10.2337/db07-1781

  54. 54.

    Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267-273.

    Not in our library10.1038/ng1180

  55. 55.

    Mottis A, Mouchiroud L, Auwerx J. Emerging roles of the corepressors NCoR1 and SMRT in homeostasis. Genes Dev. 2013;27:819-835.

    Not in our library10.1101/gad.214023.113

  56. 56.

    Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, Clementi E, et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 2005;310:314-317.

    Not in our library10.1126/science.1117728

  57. 57.

    O'Neill HM, Maarbjerg SJ, Crane JD, Jeppesen J, Jorgensen SB, Schertzer JD, Shyroka O, Kiens B, van Denderen BJ, Tarnopolsky MA, et al. AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc Natl Acad Sci USA. 2011;108:16092-16097.

    Not in our library10.1073/pnas.1105062108

  58. 58.

    Otera H, Ishihara N, Mihara K. New insights into the function and regulation of mitochondrial fission. Biochim Biophys Acta. 2013;1833:1256-1268.

    Not in our library10.1016/j.bbamcr.2013.02.002

  59. 59.

    Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, Jenkins AB, Storlien LH. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997;46:983-988.

    Not in our library10.2337/diab.46.6.983

  60. 60.

    Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA. 2003;100:8466-8471.

    Not in our library10.1073/pnas.1032913100

  61. 61.

    Peng C, Lu Z, Xie Z, Cheng Z, Chen Y, Tan M, Luo H, Zhang Y, He W, Yang K, et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics. 2011;10:M111 012658.

    Not in our library10.1074/mcp.m111.012658

  62. 62.

    Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003;300:1140-1142.

    Not in our library10.1126/science.1082889

  63. 63.

    Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350:664-671.

    Not in our library10.1056/nejmoa031314

  64. 64.

    Pospisilik JA, Knauf C, Joza N, Benit P, Orthofer M, Cani PD, Ebersberger I, Nakashima T, Sarao R, Neely G, et al. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell. 2007;131:476-491.

    Not in our library10.1016/j.cell.2007.08.047

  65. 65.

    Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010;12:662-667.

    Not in our library10.1016/j.cmet.2010.11.015

  66. 66.

    Samant SA, Zhang HJ, Hong Z, Pillai VB, Sundaresan NR, Wolfgeher D, Archer SL, Chan DC, Gupta MP. SIRT3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress. Mol Cell Biol. 2014;34:807-819.

    Not in our library10.1128/mcb.01483-13

  67. 67.

    Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta. 2011;1813:1269-1278.

    Not in our library10.1016/j.bbamcr.2010.09.019

  68. 68.

    Schneeberger M, Dietrich MO, Sebastian D, Imbernon M, Castano C, Garcia A, Esteban Y, Gonzalez-Franquesa A, Rodriguez IC, Bortolozzi A, et al. Mitofusin 2 in POMC neurons connects ER stress with leptin resistance and energy imbalance. Cell. 2013;155:172-187.

    Not in our library10.1016/j.cell.2013.09.003

  69. 69.

    Schooneman MG, Vaz FM, Houten SM, Soeters MR. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes. 2013;62:1-8.

    Not in our library10.2337/db12-0466

  70. 70.

    Schwer B, Eckersdorff M, Li Y, Silva JC, Fermin D, Kurtev MV, Giallourakis C, Comb MJ, Alt FW, Lombard DB. Calorie restriction alters mitochondrial protein acetylation. Aging Cell. 2009;8:604-606.

    Not in our library10.1111/j.1474-9726.2009.00503.x

  71. 71.

    Sebastian D, Hernandez-Alvarez MI, Segales J, Sorianello E, Munoz JP, Sala D, Waget A, Liesa M, Paz JC, Gopalacharyulu P, et al. Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis. Proc Natl Acad Sci USA. 2012;109:5523-5528.

    Not in our library10.1073/pnas.1108220109

  72. 72.

    Soriano FX, Liesa M, Bach D, Chan DC, Palacin M, Zorzano A. Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha, estrogen-related receptor-alpha, and mitofusin 2. Diabetes. 2006;55:1783-1791.

    Not in our library10.2337/db05-0509

  73. 73.

    Storlien L, Oakes ND, Kelley DE. Metabolic flexibility. Proc Nutr Soc. 2004;63:363-368.

    Not in our library10.1079/pns2004349

  74. 74.
  75. 75.

    Villani G, Greco M, Papa S, Attardi G. Low reserve of cytochrome c oxidase capacity in vivo in the respiratory chain of a variety of human cell types. J Biol Chem. 1998;273:31829-31836.

    Not in our library10.1074/jbc.273.48.31829

  76. 76.

    Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012;23:351-363.

    Not in our library10.1016/j.tem.2012.05.001

  77. 77.

    Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. 2003;113:159-170.

    Not in our library10.1016/s0092-8674(03)00269-1

  78. 78.
  79. 79.

    Wredenberg A, Freyer C, Sandstrom ME, Katz A, Wibom R, Westerblad H, Larsson NG. Respiratory chain dysfunction in skeletal muscle does not cause insulin resistance. Biochem Biophys Res Commun. 2006;350:202-207.

    Not in our library10.1016/j.bbrc.2006.09.029

  80. 80.

    Yamamoto H, Williams EG, Mouchiroud L, Canto C, Fan W, Downes M, Heligon C, Barish GD, Desvergne B, Evans RM, et al. NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. Cell. 2011;147:827-839.

    Not in our library10.1016/j.cell.2011.10.017

  81. 81.

    Yoon M. The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. Pharmacol Res. 2009;60:151-159.

    Not in our library10.1016/j.phrs.2009.02.004

  82. 82.

    Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14:528-536.

    Not in our library10.1016/j.cmet.2011.08.014

  83. 83.

    Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011;12:9-14.

    Not in our library10.1038/nrm3028

  84. 84.

    Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337:1062-1065.

    Not in our library10.1126/science.1219855

  85. 85.

    Zechner C, Lai L, Zechner JF, Geng T, Yan Z, Rumsey JW, Collia D, Chen Z, Wozniak DF, Leone TC, et al. Total skeletal muscle PGC-1 deficiency uncouples mitochondrial derangements from fiber type determination and insulin sensitivity. Cell Metab. 2010;12:633-642.

    Not in our library10.1016/j.cmet.2010.11.008

Cited by papers we hold 6

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.